169 related articles for article (PubMed ID: 36574856)
1. Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway.
Ying Z; van Eenige R; Beerepoot R; Boon MR; Kloosterhuis NJ; van de Sluis B; Bartelt A; Rensen PCN; Kooijman S
Pharmacol Res; 2023 Jan; 187():106634. PubMed ID: 36574856
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Hoeke G; Wang Y; van Dam AD; Mol IM; Gart E; Klop HG; van den Berg SM; Pieterman EH; Princen HMG; Groen AK; Rensen PCN; Berbée JFP; Boon MR
Atherosclerosis; 2017 Dec; 267():116-126. PubMed ID: 29121499
[TBL] [Abstract][Full Text] [Related]
3. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development.
Berbée JF; Boon MR; Khedoe PP; Bartelt A; Schlein C; Worthmann A; Kooijman S; Hoeke G; Mol IM; John C; Jung C; Vazirpanah N; Brouwers LP; Gordts PL; Esko JD; Hiemstra PS; Havekes LM; Scheja L; Heeren J; Rensen PC
Nat Commun; 2015 Mar; 6():6356. PubMed ID: 25754609
[TBL] [Abstract][Full Text] [Related]
4. Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.
Sui W; Li H; Yang Y; Jing X; Xue F; Cheng J; Dong M; Zhang M; Pan H; Chen Y; Zhang Y; Zhou Q; Shi W; Wang X; Zhang H; Zhang C; Zhang Y; Cao Y
Proc Natl Acad Sci U S A; 2019 May; 116(22):10937-10942. PubMed ID: 31085638
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.
Liu C; Schönke M; Zhou E; Li Z; Kooijman S; Boon MR; Larsson M; Wallenius K; Dekker N; Barlind L; Peng XR; Wang Y; Rensen PCN
Cardiovasc Res; 2022 Jan; 118(2):489-502. PubMed ID: 33693480
[TBL] [Abstract][Full Text] [Related]
7. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice.
Liu C; Song Z; Li Z; Boon MR; Schönke M; Rensen PCN; Wang Y
Int J Obes (Lond); 2023 Mar; 47(3):236-243. PubMed ID: 36732416
[TBL] [Abstract][Full Text] [Related]
8. Aging attenuates diurnal lipid uptake by brown adipose tissue.
In Het Panhuis W; Schönke M; Siebeler R; Afkir S; Baelde R; Pronk ACM; Streefland TCM; Sips HCM; Lalai RA; Rensen PCN; Kooijman S
Aging (Albany NY); 2022 Oct; 14(19):7734-7751. PubMed ID: 36202134
[TBL] [Abstract][Full Text] [Related]
9. Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans.
Ying Z; Tramper N; Zhou E; Boon MR; Rensen PCN; Kooijman S
Cardiovasc Res; 2023 May; 119(4):905-918. PubMed ID: 35944189
[TBL] [Abstract][Full Text] [Related]
10. Role of Brown Fat in Lipoprotein Metabolism and Atherosclerosis.
Hoeke G; Kooijman S; Boon MR; Rensen PC; Berbée JF
Circ Res; 2016 Jan; 118(1):173-82. PubMed ID: 26837747
[TBL] [Abstract][Full Text] [Related]
11. Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice.
Wang S; Miller B; Matthan NR; Goktas Z; Wu D; Reed DB; Yin X; Grammas P; Moustaid-Moussa N; Shen CL; Lichtenstein AH
Nutr Res; 2013 Dec; 33(12):1072-82. PubMed ID: 24267047
[TBL] [Abstract][Full Text] [Related]
12. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
13. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
[TBL] [Abstract][Full Text] [Related]
14. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice.
Geerling JJ; Boon MR; van der Zon GC; van den Berg SA; van den Hoek AM; Lombès M; Princen HM; Havekes LM; Rensen PC; Guigas B
Diabetes; 2014 Mar; 63(3):880-91. PubMed ID: 24270984
[TBL] [Abstract][Full Text] [Related]
15. Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development.
Zhou E; Hoeke G; Li Z; Eibergen AC; Schonk AW; Koehorst M; Boverhof R; Havinga R; Kuipers F; Coskun T; Boon MR; Groen AK; Rensen PCN; Berbée JFP; Wang Y
Cardiovasc Res; 2020 Aug; 116(10):1710-1720. PubMed ID: 31589318
[TBL] [Abstract][Full Text] [Related]
16. The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE
Shen Y; Gu HM; Zhai L; Wang B; Qin S; Zhang DW
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Oct; 1867(10):159196. PubMed ID: 35803528
[TBL] [Abstract][Full Text] [Related]
17. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE.
van Dijk KW; van Vlijmen BJ; van't Hof HB; van der Zee A; Santamarina-Fojo S; van Berkel TJ; Havekes LM; Hofker MH
J Lipid Res; 1999 Feb; 40(2):336-44. PubMed ID: 9925664
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
Huang Y; Liu XQ; Rall SC; Mahley RW
J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
